Cargando…

Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases

BACKGROUND: It remains uncertain if prior use of oral anticoagulants (OACs) in COVID-19 outpatients with multimorbidity impacts prognosis, especially if cardiometabolic diseases are present. Clinical outcomes 30-days after COVID-19 diagnosis were compared between outpatients with cardiometabolic dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rivera-Caravaca, José Miguel, Harrison, Stephanie L., Buckley, Benjamin J. R., Fazio-Eynullayeva, Elnara, Underhill, Paula, Marín, Francisco, Lip, Gregory Y. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417638/ https://www.ncbi.nlm.nih.gov/pubmed/34481513 http://dx.doi.org/10.1186/s12933-021-01368-6

Ejemplares similares

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2021)

Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data
por: Buckley, Benjamin J. R., et al.
Publicado: (2021)

Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis
por: Harrison, Stephanie L., et al.
Publicado: (2020)

Atrial fibrillation and the risk of 30‐day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID‐19
por: Harrison, Stephanie L., et al.
Publicado: (2020)

End-Stage renal disease and 30-day mortality for adults with and without COVID-19
por: Harrison, Stephanie L., et al.
Publicado: (2021)

Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications
por: Camelo-Castillo, Anny, et al.
Publicado: (2021)

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists
por: Roldán, Vanessa, et al.
Publicado: (2022)

Exercise‐Based Cardiac Rehabilitation and All‐Cause Mortality Among Patients With Atrial Fibrillation
por: Buckley, Benjamin J. R., et al.
Publicado: (2021)

Association of Exercise-Based Cardiac Rehabilitation with Progression of Paroxysmal to Sustained Atrial Fibrillation
por: Buckley, Benjamin J. R., et al.
Publicado: (2021)

Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics
por: Sánchez-Fuentes, Ana, et al.
Publicado: (2022)

Non‐vitamin K oral anticoagulants versus vitamin K antagonists in post transcatheter aortic valve replacement patients with clinical indication for oral anticoagulation: A meta‐analysis
por: Chen, Yi‐feng, et al.
Publicado: (2022)

Anticoagulation Quality and Complications of using Vitamin K Antagonists in the Cardiac Surgery Outpatient Clinic
por: da Costa, Mário Augusto Cray, et al.
Publicado: (2016)

Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review
por: Violi, Francesco, et al.
Publicado: (2016)

Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
por: Farinha, José Maria, et al.
Publicado: (2022)

Clinical implications of different types of dementia in patients with atrial fibrillation: Insights from a global federated health network analysis
por: Proietti, Riccardo, et al.
Publicado: (2023)

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Comparison of uninterrupted direct oral anticoagulation with vitamin‐K antagonists during AF‐ablation in the clinical routine. A single center register
por: Christoph, Marian, et al.
Publicado: (2021)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Comparison Between Non–vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism
por: Chen, Dong-Yi, et al.
Publicado: (2021)

Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non–vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage
por: Tsai, Chuan-Tsai, et al.
Publicado: (2020)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants
por: Pastori, Daniele, et al.
Publicado: (2018)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists
por: Dongre, Kanchan, et al.
Publicado: (2022)

Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons
por: Verdecchia, Paolo, et al.
Publicado: (2014)

Evolving Effect of the COVID-19 Pandemic on Cancer-Related Encounters
por: London, Jack W., et al.
Publicado: (2022)

207. Burden of Post-Transplant Neutropenia and Leukopenia among Kidney Transplant Recipients: A Multi-Institutional Real-World Observational Study
por: Raval, Amit D, et al.
Publicado: (2022)

Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study
por: Yu, Dahai, et al.
Publicado: (2020)

Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis
por: Wang, Kang-Ling, et al.
Publicado: (2015)

Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials
por: Domek, Magdalena, et al.
Publicado: (2020)

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
por: Dincq, Anne-Sophie, et al.
Publicado: (2014)

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
por: Malagù, Michele, et al.
Publicado: (2023)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9bdceg57uvcnoignp04ddgsj3o